- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02552238
Evaluation of Safety and Efficacy of Lumason/SonoVue in Subjects Undergoing Pharmacologic Stress BR1-142
A Prospective Multicenter Phase III Clinical Evaluation of the Safety and Efficacy of Lumason™/SonoVue® in Subjects Undergoing Pharmacologic Stress Echocardiography With Dobutamine for the Diagnosis of Coronary Artery Disease
Study Overview
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Bruxelles, Belgium, 1200
- Cliniques Universitaires Saint-Luc Unité de Pathologie Cardio-Vasculaire / Cardiologie
-
Edegem, Belgium, 2650
- Antwerp University Hospital
-
-
-
-
Ontario
-
Toronto, Ontario, Canada, M5B 1W8
- St. Michael's Hospital
-
-
-
-
-
London, United Kingdom, W12 0HS
- Hammersmith Hospital
-
-
Middlesex
-
Harrow, Middlesex, United Kingdom, HA1 3UJ
- Northwick Park Hospital
-
-
-
-
California
-
Santa Ana, California, United States, 92704
- Coastal Multi-Specialty Research, Coastal Heart Medical Group
-
-
Delaware
-
Wilmington, Delaware, United States, 19803
- Alfieri Cardiology
-
-
Florida
-
Homestead, Florida, United States, 33030
- Homestead Cardiac and Vein Center
-
-
Louisiana
-
New Orleans, Louisiana, United States, 70121
- Ochsner Clinic Foundation
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- St. Louis University Hospital
-
-
Nebraska
-
Omaha, Nebraska, United States, 68198
- University of Nebraska Medical Center
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Duke University Medical Center Cardiac Diagnostic Unit
-
-
Texas
-
Galveston, Texas, United States, 77555
- University of Texas Medical Branch at Galveston
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Provided written Informed Consent and comply with protocol requirements;
- Was at least 18 years of age;
- Had suspected of having CAD and undergoing coronary angiography within 6 months after the LUMASON DSE.
- Had undergone a previous echocardiography prior to enrollment; resulting in suboptimal unenhanced images at rest, defined as ≥ 2 suboptimal adjacent segments in any apical view.
Exclusion Criteria:
• Was a pregnant or lactating female. Exclude the possibility of pregnancy: by testing on site at the institution (serum or urine βHCG) within 24 hours prior to the start of LUMASON administration(s), by surgical history (e.g., tubal ligation or hysterectomy), post menopausal with a minimum 1 year without menses;
- Had any known hypersensitivity to 1 or more ingredients of LUMASON (sulfur hexafluoride or to any components of LUMASON);
- Had any known hypersensitivity to dobutamine;
- Had an ongoing or recent (within the last 30 days) acute myocardial infarction;
- Had known right-to-left, bidirectional or transient cardiac shunt (ruled out with agitated saline study performed before administration of LUMASON);
- Had electrolyte (especially potassium and magnesium) abnormalities;
- Had unstable pulmonary and/or systemic hemodynamic conditions e.g.:
decompensated or inadequately controlled congestive heart failure (NYHA Class IV);
- hypovolemia;
- uncontrolled hypertension, i.e. resting systolic blood pressure >200 mmHg or diastolic blood pressure >110 mmHg;
- unstable angina;
- acute coronary syndrome;
- aortic dissection;
- acute pericarditis,
- myocarditis, or endocarditis;
- stenosis of the main left coronary artery;
- hemodynamically significant outflow obstruction of the left ventricle, including hypertrophic obstructive cardiomyopathy;
- hemodynamically significant cardiac valvular defect;
- acute pulmonary embolism;
- Had uncontrolled cardiac arrhythmias;
- Had significant disturbance in conduction;
- Had hypertrophic subaortic stenosis;
- Had an acute illness (e.g., infections, hyperthyroidism, or severe anemia);
- Was previously entered into this study or received an investigational compound within 30 days before admission into this study;
- Had been treated with any other contrast agent either intravascularly or orally within 48 hours of the first LUMASON administration;
- Had any medical condition or other circumstances which would significantly decrease the chances of obtaining reliable data, achieving study objectives, or completing the study and/or postdose follow-up examinations;
In addition, due to the use of Atropine in subjects who had not reached targeted heart rate with peak dobutamine infusion, subjects with the following were excluded:
- Glaucoma;
- Pyloric stenosis;
- Prostatic hypertrophy.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Lumason
Lumason (sulfur hexafluoride lipid-type A microspheres) 2 mL IV injection
|
Lumason (sulfur hexafluoride-type A microspheres) an ultrasound contrast agent was administered as 2 single 2-mL IV injections during rest and stress echocardiography
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Sensitivity and Specificity of Lumason Enhanced Dobutamine Stress Echo (DSE) for Detection or Exclusion of Coronary Artery Disease (CAD)
Time Frame: Participants were followed until they had coronary angiography or up to 6 months post dose to collect clinical information on cardiac events if no coronary angiography were performed
|
The diagnostic performance of the echocardiographic images was compared to the truth standard to determine sensitivity and specificity. A diagnosis of CAD was determined for both the echo images and truth standard (positive diagnosis for CAD is defined as >/= 50% stenosis of any vessel on coronary angiography or if no coronary angiography was performed the occurence of a cardiac event based on clinical information for up to 6 months post dose; otherwise the diagnosis was negative). Results for sensitivity and specificity are reflected based on difference between contrast enhanced stress echo and unenhanced stress echo. Results for analysis of data based on majority assessment from the three off-site blinded readers are presented. Sensitivity and specificity are the percentages of correctly diagnosed subjects by stress echo over the total positive and negative subjects according to the truth standard respectively. |
Participants were followed until they had coronary angiography or up to 6 months post dose to collect clinical information on cardiac events if no coronary angiography were performed
|
Reader-Specific Percentages of Participants Identified as Having a Critical Shift From Suboptimal to Optimal Echocardiographic Images
Time Frame: Participants were followed until they had coronary angiography or up to 6 months post dose to collect clinical information on cardiac events if no coronary angiography was performed
|
The percentage of subjects with suboptimal images (defined as >= 2 adjacent segments with inadequate LV EBD in any of the 3 apical views) at unenhanced stress echo converted to adequate (reduction of suboptimal segments in any of the 3 apical views) at contrast-enhanced stress echo
|
Participants were followed until they had coronary angiography or up to 6 months post dose to collect clinical information on cardiac events if no coronary angiography was performed
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Total LV EBD
Time Frame: Participants were followed until they had coronary angiography or up to 6 months post dose to collect clinical information on cardiac events if no coronary angiography was performed
|
Measured as the change in the total LV EBD score based on the 17 segments, from peak stress unenhanced vs. peak stress contrast-enhanced.
Total LV EBD score ranges from 0 to 34 and higher score is better outcome.
|
Participants were followed until they had coronary angiography or up to 6 months post dose to collect clinical information on cardiac events if no coronary angiography was performed
|
Number of Participants With Adverse Events
Time Frame: 72 hours post dose
|
To obtain safety data in subjects administered Lumason during echocardiography
|
72 hours post dose
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- BR1-142
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Artery Disease
-
Elixir Medical CorporationIstituto Clinico HumanitasActive, not recruitingCoronary Artery Disease | Chronic Total Occlusion of Coronary Artery | Multi Vessel Coronary Artery Disease | Bifurcation of Coronary Artery | Long Lesions Coronary Artery DiseaseItaly
-
Fundación EPICActive, not recruitingCoronary Artery Disease | Left Main Coronary Artery Disease | Left Main Coronary Artery Stenosis | Restenosis, CoronarySpain
-
Peking Union Medical College HospitalRecruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
Peking Union Medical College HospitalNot yet recruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
IGLESIAS Juan FernandoUniversity of BernNot yet recruiting
-
National Institutes of Health Clinical Center (CC)National Heart, Lung, and Blood Institute (NHLBI)CompletedCoronary Arteriosclerosis | Coronary Artery Disease (CAD) | Obstructive Coronary Artery DiseaseUnited States
-
Barts & The London NHS TrustImperial College London; Brunel UniversityNot yet recruitingCORONARY ARTERY DISEASE
-
Fundación EPICRecruitingCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Left Main Coronary Artery Disease | Coronary Artery StenosisSpain
-
Abbott Medical DevicesCompletedCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Chronic Total Occlusion of Coronary Artery | Coronary Restenosis | Coronary Artery Stenosis | Coronary Artery RestenosisBelgium
-
San Luigi Gonzaga HospitalRecruitingCoronary Disease | STEMI | Coronary Artery Ectasia | Right Coronary Artery Occlusion | Right Coronary Artery StenosisSpain, Italy
Clinical Trials on Lumason
-
David MooneyRecruitingAbdominal InjuryUnited States
-
David MooneyTerminatedAbdominal InjuryUnited States
-
Boston Children's HospitalNot yet recruitingVesico-Ureteral RefluxUnited States
-
Indiana UniversityTerminatedLiver BiopsyUnited States
-
University of NebraskaRecruitingStress EchocardiographyUnited States
-
Children's Hospital of PhiladelphiaBracco Diagnostics, IncRecruitingDevelopmental Dysplasia of the HipUnited States
-
University of California, Los AngelesBurl Concepts, Inc.CompletedStroke, AcuteUnited States
-
Indiana UniversityRecruitingRenal Malignant TumorUnited States
-
H. Lee Moffitt Cancer Center and Research InstituteTerminatedHepatocellular Carcinoma | Liver CancerUnited States
-
Children's Mercy Hospital Kansas CityCompleted